Ethnicity and psychopharmacology

Journal of Psychopharmacology

Volumn 22, Issue 6, 2008, Pages 673-680

  Chaudhry, I B ^a   Neelam, K ^b   Duddu, V ^b   Husain, N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASHIRE CARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics; Cytochrome P450 enzyme system; Ethnicity; Psychopharmacology; Psychotropics

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; DIAZEPAM; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGRANULOCYTOSIS; BIPOLAR DISORDER; CULTURAL FACTOR; DEPRESSION; DIABETES MELLITUS; DIET; DRUG METABOLISM; DRUG RESPONSE; DRUG USE; ETHNIC DIFFERENCE; ETHNICITY; EXTRAPYRAMIDAL SYNDROME; GENETIC VARIABILITY; HEALTH BEHAVIOR; HEALTH BELIEF; HUMAN; MOTOR DYSFUNCTION; NEUTROPENIA; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RACE DIFFERENCE; REVIEW; SCHIZOPHRENIA;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; CLOZAPINE; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; HUMANS; INDIVIDUALITY; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 50249163839     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107082105     Document Type: Review

References (87)

1. Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., Ingelman S. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278: 441-446
2. Alvares A.P., Anderson K.E., Conney A.H., Kappas A. (1976) Interactions between nutritional factors and drug biotransformations in man. Proc Natl Acad Sci USA 73: 2501-2504
3. Ananth J., Kolli S., Gunatilake S., Brown S. (2005) Atypical antipsychotic drugs, diabetes and ethnicity. Expert Opin Drug Saf 4: 1111-1124
4. Anderson K.E., Kappas A. (1991) Dietary regulation of cytochrome P450. Annu Rev Nutr 11: 141-167
5. Arias T.D., Jorge L.F. (1990) Population pharmacology and ethnopharmacokinetics in 3 Amerindian groups from Panama: Cuna, Ngawbe Guaymi and Teribe. Revista Mqdica de Panamb 15: 20-26
6. Bamshad M., Wooding S., Salisbury B.A., Stephens J.C. (2004) Deconstructing the relationship between genetics and race. Nat Rev Genet 5: 598-602
7. Bertilsson L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 CYP 2D6 and 2C19. Clin Pharmacokinet 29: 192-209
8. Bertilsson L., Dahl M.L., Tybring G. (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391: 14-21
9. Binder E.B., Holsboer F. (2006) Pharmacogenomics and antidepressant drugs. Ann Med 38: 82-94
10. Binder R.L., Levy R. (1981) Extrapyramidal reactions in Asians. Am J Psychiatry 138: 1243-1244
11. Birchwood M., Cochrane R., Macmillan F., Copestake S., Kucharska J., Carriss M. (1992) The influence of ethnicity and family structure on relapse in first-episode schizophrenia. A comparison of Asian, Afro-Caribbean, and white patients. Br J Psychiatry 161: 783-790
12. Bjornsson T.D., Wagner A.J., Donahue S.R. (2003) A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 43: 943-967
13. Bogner H.R., Lin J.Y., Morales K.H. (2006) Patterns of early adherence to the antidepressant citalopram among older primary care patients: The PROSPECT Study. Int J Psychiatry Med 36: 103-119
14. Bond W.S. (1991) Ethnicity and psychotropic drugs. Clin Pharmcol 10: 467-470
15. Bradford L.D., Kirlin W.G. (1998) Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int J Neuropsychopharmcol 1: 173-185
16. Branch R.A., Salih S.Y., Homeida M. (1978) Racial differences in drug metabolizing ability: a study with antipyrine in the Sudan. Clin Pharmacol Ther 24: 283-286
17. Carbajal D., Casaco A., Arruzazabala L., Gonzalez R., Fuentes V. (1991) Pharmacological screening of plant decoctions commonly used in Cuban folk medicine. J Ethnopharmacol 33: 21-24
18. Chaturvedi N. (2001) Ethnicity as an epidemiological determinant - crudely racist or crucially important? Int J Epidemiol 30: 925-927
19. Chaudhry I.B., Waheed W., Malik O., Vadhari R., Badshah S., Husain N. (2006) Ethnic disparities in the use of atypical antipsychotics and treatment outcomes in first episode psychosis patients in a multi-ethnic population. J Psychopharmacol 20: A20
20. Citrome L., Levine J., Allingham B. (1996) Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 32: 321
21. Citrome L.L. (2004) The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today 40: 445-464
22. Cohen D. (2004) Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 37: 1-11
23. Conney A.H., Pantuck E.J., Hsiao K.C., Garland W.A., Anderson K.E., Alvares A.P., Kappas A. (1976) Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 20: 633-642
24. Dandara C., Masimirembwa C.M., Magimba A., Sayi J., Kaaya S., Sommers D.K., Snyman J.R., Hasler J.A. (2001) Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern-African populations including psychiatric patients. Eur J Clin Pharmacol 57: 11-17
25. Desai N.K., Sheth U.K., Mucklow J.C., Fraser H.S., Bulpitt C.J., Jones S.W., Dollery C.T. (1980) Antipyrene clearance in Indian villagers. Br J Clin Pharmacol 9: 387-394
26. Diaz E., Woods S.W., Rosenheck R.A. (2005) Effects of ethnicity on psychotropic medications adherence. Community Ment Health J 41: 521-537
27. Doyle J.M. (2006) What race and ethnicity measure in pharmacologic research. J Clin Pharmacol 46: 401-404
28. Fearon P., Kirkbride J.B., Morgan C., Dazzan P., Morgan K., Lloyd T., Hutchinson G., Tarrant J., Fung W.L., Holloway J., Mallett R., Harrison G., Leff J., Jones P.B., Murray R.M. (2006) Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP study. Psychol Med 36: 1541-1550
29. Frackiewicz E.J., Sramek J.J., Herrera J.M., Kurtz N.M., Cutler N.R. (1997) Ethnicity and antipsychotic response. Ann Pharmacother 31: 1360-1369
30. Froemming J.S., Lam Y.W., Jann M.W., Davis C.M. (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet 17: 396-423
31. Fukuma Y., Kashimura S., Umetsu K., Yuasa I., Suzuki T. (1990) Genetic variation of alpha-2-HS-glycoprotein in the Kyushu district of Japan: description of three new rare variants. Hum Hered 40: 49-51
32. Ghoneim M.M., Korttila K., Chiang C.K., Jacobs L., Schoenwald R.D., Mewaldt S.P., Kayaba K.O. (1981) Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 29: 749-756
33. Gonzalez F.J., Idle J.R. (1994) Pharmacogenetic phenotyping and genotyping present status and future potential. Clin Pharmacokinet 26: 59-70
34. Goodman A.H. (2001) Why genes don't count (for racial differences in health). Am J Public Health 90: 1699-1702
35. Gudjonsson H.G., Rabe-Hesketh S. (2004) Management of psychiatric in-patient violence. Br J Psychiatry 184: 258-264
36. Harris R.Z., Jang G.R., Tsunoda S. (2003) Dietary effects on drug metabolism and transport. Clin Pharmacokinet 42: 1071-1088
37. Hashemi J., Kheirabadi G., Movahedian A. (2006) Lithium ratio in bipolar patients in Isfahan, Iran. J Res Med Sci 11: 257-262
38. Herbeck D.M., West J.C., Ruditis I., Duffy F.F., Fitek D.J., Bell C.C., Snowden L.R. (2004) Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 55: 677-684
39. Hull S.A., Cornwell J., Harvey C., Eldridge S., Bare P.O. (2001) Prescribing rates for psychotropic medication amongst east London general practices: low rates where Asian populations are greatest. Fam Pract 18: 167-173
40. Ingelman-Sundberg M., Johansson I., Dahl M.L., Bertilsson L., Yue Q.Y., Sjoqvist F. (1992) Genotyping for drug metabolism capacity can give valuable clinical information. Lakartidningen 89: 1675-1678
41. Jefferson J.W. (1998) Drug and diet interactions: avoiding therapeutic paralysis. J Clin Psychiatry 59 (Suppl. 16). 31-39
42. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjoqvist F., Ingelman S. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90: 11825-11829
43. Juneja R.K., Weitkamp L.R., Stratil A., Gahne B., Guttormsen S.A. (1988) Further studies of the plasma alpha 1 B-glycoprotein polymorphism: two new alleles and allele frequencies in Caucasians and in American blacks. Hum Hered 38: 267-272
44. Kagimoto M., Heim M., Kagimoto K., Zeugin T., Meyer U.A. (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265: 17209-17214
45. Kalow W. (1989) Genetic polymorphism in drug oxidation. Psychopharmacol Ser 7: 148-162
46. Kalow W. (2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 6: 162-165
47. Kelly D.L., Kreyenbuhl J., Dixon L., Love R.C., Medoff D., Conley R.R. (2006) Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull. DOI:10.1093/schbul/sblo68
48. Knudsen H.K., Ducharme L.J., Roman P.M. (2007) Racial and ethnic disparities in SSRI availability in substance abuse treatment. Psychiatr Serv 58: 55-62
49. Kremer J.M., Wilting J., Janssen L.H. (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40: 1-47
50. Kreyenbuhl J., Zito J.M., Buchanan R.W., Soeken K.L., Lehman A.F. (2003) Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 29: 183-193
51. Kuno E., Rothbard A.B. (2002) Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 159: 567-572
52. Lee C.F., Yang Y.Y., Hu O Y P (1998) Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients 234. Aust N Z J Psychiatry 32: 133-136
53. Leese M., Thornicroft G., Shaw J., Thomas S., Mohan R., Harty M.A., Dolan M. (2006) Ethnic differences among patients in high-security psychiatric hospitals in England. Br J Psychiatry 188: 380-385
54. Lieberman J.A., Yunis J., Egea E., Canoso R.T., Kane J.M., Yunis E.J. (1990) HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 47: 945-948
55. Lilja J.J., Kivisto K.T., Backman J.T., Lamberg T.S., Neuvonen P.J. (1998) Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64: 655-660
56. LLerena A., Herraiz A.G., Cobaleda J., Johansson I., Dahl M.L. (1993) Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 54: 606-611
57. Mallett R., Leff J., Bhugra D., Pang D., Zhao J.H. (2002) Social environment, ethnicity and schizophrenia: a case-control study. Soc Psychiatry Psychiatr Epidemiol 37: 329-335
58. Mallinger J.B., Fisher S.G., Brown T., Lamberti J.S. (2006) Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 57: 133-136
59. Mallinger J.B., Lamberti J.S. (2006) Clozapine - should race affect prescribing guidelines? Schizophr Res 83: 107-108
60. Masimirembwa C., Hasler J., Bertilssons L., Johansson I., Ekberg O., Ingelman S. (1996) Phenotype and genotype analysis of debrisoquine hydroxylase CYP2D6 in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51: 117-122
61. Masimirembwa C.M., Johansson I., Hasler J.A., Ingelman S. (1993) Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 3: 275-280
62. Matchar D.B., Thakur M.E., Grossman I., McCrory D.C., Orlando L.A., Steffens D.C., Goldstein D.B., Cline K.E., Gray R.N. (2007) Testing for Cytochrome P450 Polymorphisms in Adults with Non-Psychotic Depression Treated With Selective Serotonin Reuptake Inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146. (Prepared by the Duke Evidence-based Practice Center under Contract No. 29002-0025.) AHRQ Publication No. 7-E002. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/downloads/pub/evidence/ pdf/cyp450/cyp450.pdf
63. Matsuda K.T., Cho M.C., Lin K.M., Smith M.W., Young A.S., Adams J.A. (1996) Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 32: 253-257
64. McLeod H.L. (2001) Pharmacogenetics: more than skin deep. Nat Genet 29: 247-248
65. Miskimen T., Marin H., Escobar J. (2003) Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology 171: 98-104
66. Morgan C., Mallett R., Hutchinson G., Leff J. (2004) Negative pathways to psychiatric care and ethnicity: the bridge between social science and psychiatry. Soc Sci Med 58: 739-752
67. Ng C.H., Chong S., Lambert T., Fan A., Hackett L.P., Mahendran R., Subramaniam M., Schweitzer M. (2005) An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 20: 163-168
68. Okuma T. (1981) Differential sensitivity to the effects of psychotropic drugs: psychotics vs normals; Asian vs Western populations. Folia Psychiatr Neurol Jpn 35: 79-87
69. Opolka J.L., Rascati K.L., Brown C.M., Gibson P.J. (2004) Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 55: 151-156
70. Patel N.C., DelBello P.M., Keck P.E., Strakowski S.M. (2005) Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 15: 938-946
71. Pollock B.G., Mulsant B.H., Sweet R.A., Rosen J., Altieri L.P. (1995) Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 31: 327-331
72. Relling M.V., Cherrie J., Schell M.J., Petros W.P., Meyer W.H., Evans W.E. (1991) Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 50: 308-313
73. Rosenblat R., Tang S.W. (1987) Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with occidentals. Can J Psychiatry 32: 270-274
74. Ruiz P., Varner R.V., Small D.R., Johnson B.A. (1999) Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q 70: 163-172
75. Selten J.P., Cantor-Grae E., Kahn R.S. (2007) Migration and schizophrenia. Curr Opin Psychiatry 20: 111-115
76. Shader R.I., Greenblatt D.J. (1988) Bees, ginseng and MAOIs revisited. J Clin Psychopharmacol 8: 235
77. Smith G., Harrison D.J., East N., Rae F., Wolf H., Wolf C.R. (1993) Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts. Br J Cancer 68: 57-63
78. Sramek J.J., Pi E.H. (1996) Ethnicity and antidepressant response. Mt Sinai J Med 63: 320-325
79. Strickland T.L., Lin K.M., Fu P., Anderson D., Zheng Y. (1995) Comparison of lithium ratio between African-American and caucasian bipolar patients 245. Biolo Psychiatry 37: 325-330
80. Strickland T.L., Stein R., Lin K.M., Risby E., Fong R. (1997) The pharmacologic treatment of anxiety and depression in African Americans Considerations for the general practitioner. Arch Fam Med 6: 371-375
81. Taylor D.M. (2004) Prescribing of clozapine and olanzapine: dosage, polypharmacy and patient ethnicity. Psychiatric Bull 28 (7). 241-243
82. Varner R.V., Ruiz P., Small D.R. (1998) Black and white patients response to antidepressant treatment for major depression. Psychiatr Q 69: 117-125
83. Walkup J.T., McAlpine D.D., Olfson M., Labay L.E., Boyer C., Hansell S. (2000) Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 61: 344-348
84. Wang P. S, West J.C., Tanielian T., Pincus H.A. (2000) Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 26: 451-457
85. Whiskey E., Taylor D. (2007) Restarting clozapine after neutropenia evaluating the possibilities and practicalities. CNS Drugs 21: 25-35
86. Wilson J.F., Weale M.E., Smith A.C., Gratrix F., Fletcher B., Thomas M.G., Bradman N., Goldstein D.B. (2001) Population genetic structure of variable drug response. Nat Genet 29: 265-269
87. Woolhouse N.M., Andoh B., Mahgoub A., Sloan T.P., Idle J.R., Smith R.L. (1979) Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 26: 584-591